LOS ANGELES – ChromaDex Corp. (NASDAQ:CDXC) announced today that NutraIngredients, a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERP^TM) with a 2022 European NutraIngredients Award in the “Nutrition Research Project” category for developing the science behind ChromaDex’s proprietary and patented Niagen^® nicotinamide riboside (NR) ingredient. Niagen is an efficient precursor for the essential cellular coenzyme nicotinamide adenine dinucleotide (NAD⁺), which stimulates cellular energy production and supports cellular repair. Decreased NAD⁺ levels have been associated with age-related decline in overall health.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005235/en/

ChromaDex Wins 2022 NutraIngredients Award for Developing the Science Behind Niagen® (Graphic: Business Wire)

Honoring the best and brightest in ingredients, products, companies, people, and initiatives in the nutrition and dietary supplement industry, the NutraIngredients Awards spotlight innovation, long-term market success, and cutting-edge research. The Nutrition Research Project category assessed companies that showcased sound science to back up claims and inform business decisions, and awarded the best game-changing nutrition research projects that push boundaries of nutritional science.

“As a pioneer of NAD⁺ and NR science via Niagen, we are honored to receive this award and garner recognition for the innovative research CERP is leading throughout the world,” said Dr. Andrew Shao, ChromaDex Senior Vice President of Global Regulatory and Scientific Affairs. “Through CERP, we are furthering research on the benefits of Niagen and NAD⁺ by collaborating with the global research community and the NutraIngredients Award for the best Nutrition Research Project reinforces our dedication to this.”

CERP is an essential component of ChromaDex’s Research and Development Program, where Niagen and other materials (bulk, clinical, and matching placebo) are provided, in kind, for outstanding research proposals. Additionally, a group of ChromaDex interdisciplinary scientists supports the technical and intellectual property needs of investigators, presents research at conferences, and is helping to uncover the benefits of Niagen and NAD⁺ within the healthy aging research community on a global scale.

The judges for the 2022 EU NutraIngredients Awards said that “life improvement for older populations is a global challenge and demonstrating healthy aging benefits is no easy feat. [We] truly appreciated [CERP’s] solid research project based on large-scale cooperation between the body of researchers and institutions. [We] were also impressed by the expertise, diversity, and dedication of the product testing group.” (Source: NutraIngredients Awards Brochure).

“Our team has worked diligently to set a standard for excellence in industry-academic relationships and collaborations to support the scientific advancement of Niagen® and NAD⁺,” said Dr. Yasmeen Nkrumah-Elie, Global Director of Research & Development for External Research at ChromaDex. “CERP differentiates ChromaDex from other companies because the science is expansive and is primarily investigator driven, and third-party funded. This award honors our mission and we dedicate it to the investigators in our program.”

Just this April 2022, CERP celebrated over 250 material transfer agreements (MTAs) with over 235 independent scientists, researchers, doctors, and investigators across 182 institutions and 33 countries. In Europe, CERP has established 70 material transfer agreements with 58 institutions supporting research on Ataxia-telangiectasia, skeletal muscle, heart health, among others.

For additional information on ChromaDex’s 2022 NutraIngredients Award, please click www.nutraingreients-awards.com and for more on the science supporting Niagen visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the value of CERP. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could” or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005235/en/

ChromaDex Media Contact:

Kendall Knysch, Director of Media Relations

310-388-6706 ext. 689

kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:

Brianna Gerber, Vice President of Finance and Investor Relations

949-419-0288 ext. 127

briannag@chromadex.com